Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

This study is comparing 2 versus 3 cycles of a chemotherapy regimen (modified TPF) combined with an immunotherapy drug (camrelizumab) as initial (induction) treatment for locally advanced nasopharyngeal carcinoma — a type of cancer at the back of the nose, near the base of the skull. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with nasopharyngeal carcinoma at a specific advanced stage (T1-4, N2-3, M0) - You have not had any prior cancer treatment (surgery, radiation, or chemotherapy) - You have at least one tumor that can be measured on imaging - Your general health score (ECOG) is 0 or 1 and your major organs are functioning normally **You may NOT be eligible if...** - You have already received any treatment for this cancer - Your cancer has spread to distant organs - Your organ function is significantly impaired - You cannot use contraception during the study period Talk to your doctor to see if this trial is right for you.